Inspire Medical Systems, which produces an implant to treat sleep apnea, extended the run spots involving the Golden Bachelorette winner through the holidays.

Gross margin was 85.8% for the third quarter of 2025 compared to 84.1% in the third quarter of 2024. The year-over-year increase was due to higher sales volume and higher Inspire V sales mix, which ...

Around 22 million Americans have sleep apnea. Traditional continuous positive airway pressure, or CPAP, machines are the standard treatment. However, they can be loud, uncomfortable and have a pesky ...

Inspire Medical (NYSE: INSP) shares got a boost after hours today on third-quarter results that beat the consensus Wall ...

Inspire Medical Systems has reported a significant 84% rise in Q1 2023 revenue, reaching $127.9 million, driven by its innovative treatments for Obstructive Sleep Apnea. The company has received FDA ...

Medical technology company Inspire Medical Systems (NYSE:INSP) in Q3 CY2025, with sales up 10.5% year on year to $224.5 ...

The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of its ...

Doctors at ENT Head & Neck Specialists have completed the practice’s 100th Berks County procedure of Inspire — an FDA-approved obstructive sleep apnea treatment option for people who cannot use ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” third-quarter 2025 investor letter. A copy ...

Analysts are estimating that Inspire Medical Systems will report an earnings per share (EPS) of $-0.14. Anticipation ...